Trials / Recruiting
RecruitingNCT07241533
Asiaticoside for Treating Overweight/Obesity
A Clinical Efficacy Study of Asiaticoside for Treating Overweight/Obesity
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Centella asiatica is a traditional herbal medicine widely used in China and Southeast Asia for treating various conditions. Preclinical studies have shown that madecassic acid glycosides, including asiaticoside and madecassoside, can significantly reduce body weight gain, adipose tissue mass, and serum triglyceride levels in high-fat diet-induced obese mice. These compounds also improve hepatic steatosis and insulin resistance. This exploratory, interventional study aims to evaluate the clinical efficacy of orally administered asiaticoside tablets in adults with overweight or obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Asiaticoside tablets | Asiaticoside tablets 60mg tid for 12 weeks |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2025-11-21
- Last updated
- 2025-12-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07241533. Inclusion in this directory is not an endorsement.